|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fondaparinux#Contraindications]] |
| {{Fondaparinux}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Contraindications==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ARIXTRA is contraindicated in the following conditions:
| | [[Category: Anticoagulants]] |
| | |
| *Severe [[renal impairment]] ( [[creatinine clearance]] [CrCl] < 30 mL/min). [See [[Fondaparinux warnings and precautions|Warnings and Precautions]] and[[ Fondaparinux use in specific populations| Use in Specific Populations ]]]
| |
| *Active major [[bleeding]].
| |
| *Bacterial [[endocarditis]].
| |
| *[[Thrombocytopenia]] associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium.
| |
| *Body weight < 50 kg ( [[venous thromboembolism]] [[VTE]] prophylaxis only) [see [[Fondaparinux warnings and precautions|Warnings and Precautions]] ].
| |
| *History of serious [[hypersensitivity]] reaction (e.g., [[angioedema]], [[anaphylactoid]]/[[anaphylactic]] reactions) to ARIXTRA.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |